Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Lenvatinib
Related studies linked through entity extraction aliases.
Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
Lenvatinib Plus HAIC of Modified FOLFOX Regime vs Lenvatinib Plus HAIC of ROX Regime in Patients With Advanced HCC
- Status
- UNKNOWN
- Phase
- EARLY_PHASE1
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
- Status
- COMPLETED
- Phase
- PHASE2
Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma
- Status
- COMPLETED
- Phase
- PHASE2
KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent
- Status
- TERMINATED
- Phase
- PHASE2/PHASE3
Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).
- Status
- TERMINATED
- Phase
- PHASE3
Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
- Status
- COMPLETED
- Phase
- PHASE2
Study of TACE Combined With Lenvatinib to Prevent Postoperative Recurrence in Patients With MVI Positive HCC
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study
- Status
- COMPLETED
- Phase
- PHASE3
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study
- Status
- COMPLETED
- Phase
- PHASE3
Pembrolizumab and Lenvatinib in Advanced/Metastatic Neuroendocrine Prostate Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2